21
Views
29
CrossRef citations to date
0
Altmetric
Original Article

Clinical Science Review: Update on Trimetrexate, a Folate Antagonist with Antineoplastic and Antiprotozoal Properties

&
Pages 159-172 | Published online: 11 Jun 2009

References

  • Baker BR. Design of Active-Site-Directed Irreversible Enzyme Inhibitors. John Wiley and Sons, New York 1967
  • Elslager E F, Davoll J. Synthesis of fused pyrimidines as folate antagonists. Lectures in Heterocyclic Chemistry, RN. Castle, LB. Townsend. Hetero Corp. Orem, UT 1974; Vol. 2
  • McCormack JJ. Structure-activity relationships among pteridine derivatives and related quinazolines as inhibitors of dihydrofolate reductase. Chemistry and Biology of Pteridines, W Pfleiderer, W de Gruyter, New York 1975; 125–132
  • Bertino J R, Sawicki WL. Potent inhibitory activity of trimethoxyquine (TMQ), ‘nonclassical’ 2,4 diaminoquinazoline, on mammalian DNA synthesis. Proc Am Assoc Cancer Res 1977; 18: 168, abstr
  • Chen B K, Horvath C, Bertino JR. Multivariant analysis and quantitative structure-activity relationships: inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines. J Med Chem 1978; 22: 483–491
  • Bertino J R, Sawicki W L, Moroson BA, et al. 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) methyl] quinazoline (TMQ), a potent non-classical folate antagonist inhibitor-1. Biochem Pharmacol 1979; 28: 1983–1987
  • Seither R L, Goldman ID. Rapid analysis of the consequences of dihydrofolate reductase (DHRF) inhibition by methotrexate (MIX) or trimetrexate (TMQ) in L1210 cells. Proc Am Assoc Cancer Res 1988; 29: 282, abstr
  • Matherly L H, Muench SP. Role of intracellular folate binding in tetrahydrofolate (THF) depletion in antifolate-treated L1210 cells. Proc Am Assoc Cancer Res 1988; 29: 282, abstr
  • NCI Clinical Brochure for trimetrexate glucuronate. Nov, 1983
  • Latham B, Von Hoff D D, Elslager E. Use of a human tumor cloning system to evaluate analogs to methotrexate and mitoxantrone. Cancer Treat Rep 1984; 68: 733–738
  • Jackson R C, Fry D W, Boritzki TJ, et al. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Reg 1984; 22: 187–206
  • Kamen B A, Eibl B, Cashmore AR, et al. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[3,4,5-trimethoxyanilino) methyl]quinazoline), a non-classical antifolate in methotrexate-reistant leukemia cells in vitro. Biochem Pharmacol 1984; 33: 1697–1699
  • O'Dwyer P J, Shoemaker D D, Plowman J, et al. Trimetrexate: a new antifol entering clinical trials. Invest New Drugs 1985; 3: 71–75
  • Weir E C, Cashmore A R, Dreyer RN, et al. Pharmacology and toxicity of a potent ‘nonclassical’ 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982; 42: 1696–1702
  • Anderson J A, Andrews L K, de la Iglesia FA, et al. Single dose intravenous toxicity study of CI-898 (trimetrexate) in male and female albino mice. Warner-Lambert/Parke-Davis Research Report No. RR 745–00565. 1983
  • Lin J T, Cashmore A R, Baker M, et al. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology and pharmacokinetics. Cancer Res 1987; 47: 609–616
  • Donehower R C, Graham M L, Thompson GE, et al. Phase I and pharmacokinetic study of trimetrexate (TMTX) in patients with advanced cancer. Proc Am Soc Clin Oncol 1985; 4: 32, abstr
  • Legha S, Tenney D, Ho DH, et al. Phase I clinical and pharmacology study of trimetrexate (TMQ). Proc Am Soc Clin Oncol 1985; 4: 48, abstr
  • Fanucchi M P, Walsh T D, Fleischer M, et al. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 1987; 47: 3303–3308
  • Stewart J A, McCormack J J, Tong W, et al. Phase I clinical and pharmacokinetic study of trimetrexate using a daily × 5 schedule. Cancer Res 1988; 48: 5029–5035
  • Rosen M, Ohnuma T, Zimet A, et al. Phase I study of trimetrexate (TMTX, TMQ, JB-11) glucuronate in a 5-day infusion schedule. Proc Am Assoc Cancer Res 1986; 27: 172, abstr
  • Jolivet J, Landry L, Pinard M-F, et al. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169–172
  • NCI Clinical Pharmacology Branch, Phase I trial of trimetrexate: Minutes of the Phase I Working Group and the Biomedical Modulators Advisory Group. July 17–18, 1985; 129–134
  • Balis F M, Patel R, Luks E, et al. Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 1987; 47: 4973–4976
  • Sanders J, Ducore J, Kamen B, et al. A phase I trial of trimetrexate (TMTX) in children with leukemia and solid tumors. Proc Am Soc Clin Oncol 1987; 6: 44, abstr
  • Lin J, Cashmore A, Baker M, et al. Trimetrexate in metastatic colorectal cancer-early phase II results in previously treated patients. Proc Am Soc Clin One 1986; 5: 96, abstr
  • Leiby J, Capizzi R, Maroun J, et al. Phase 2 evaluation of the anticancer efficacy of trimetrexate. Proc 5th NCI-EORTC Symposium on New Drugs in Cancer Therapy 1986; 11: 20, abstr
  • Maroun J. Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer. Semin Oncol 1988; IS: 17–21, suppl 2
  • Robert F. Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 1988; 15: 22–26, suppl 2
  • Leiby JM. Trimetrexate: a phase 2 study in previously treated patients with metastatic breast cancer. Semin Oncol 1988; 15: 27–31, suppl 2
  • Alberts A S, Falkson G, Badata M, et al. Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 1988; 6: 319–321
  • Curley T, Engstrom C, Scher H, et al. Phase II trial of trimetrexate (TMTX) in hormone-refractory bidimensionally measurable (BDM) prostatic cancer (PC). Proc Am Soc Clin Oncol 1989; 8: 140, abstr
  • Quirt I, Eisenhauer E, Knowling M, et al. Phase 2 study of trimetrexate in metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 1989; 7: 275, abstr
  • Allegra C J, Chabner B A, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 978–985
  • Kovacs J A, Allegra C J, Chabner BA, et al. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J Infect Dis 1987; 155: 1027–1032
  • Allegra C J, Kovacs J A, Drake JC, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest 1987; 79: 478–482
  • De Lap R J, Grillo A J, Baukema J, et al. Investigator's brochure: trimetrexate glucuronate. Warner-Lambert/Parke-Davis Research Report No. RR-X-720–02211. 1985
  • Hooke K E, Nelson J, Roberts BJ, et al. Cell cycle effects of trimetrexate (CI-898). Cancer Chemother Pharmacol 1986; 16: 116–120
  • Diddens H, Niethammer D, Jackson RC. Patterns of crossresistance to the antifolate drugs trimetrexate, metoprine, homofolate and CB 3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 1983; 43: 5286–5292
  • Li W W, Lin J T, Bertino JR. Basis for relative efficacy of three antifolates, methotrexate (MTX), 10-ethyl,10-deazaaminopterin (10-EDAM), and trimetrexate in a rat sarcoma model. Proc Am Assoc Cancer Res 1989; 30: 515, abstr
  • Fry D W, Besserer VA. Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antfolates. Cancer Res 1988; 48: 6986–6991
  • Rodenhuis S, McGuire J J, Sawicki W L, Bertino JR. Effects of methotrexate and of the ‘neoclassical’ folate antagonist trimetrexate on human leukemia cells. Leukemia 1987; 1: 116–120
  • Theiss J C, Krishna G, Kropko M-L, et al. Effect of leucovorin (LCV) on the in vitro cytotoxic and clastogenic activity of trimetrexate (TMTX). Proc Am Assoc Cancer Res 1989; 30: 472, abstr
  • Bertino J R, Mini E, Sobrero A, et al. Methotrexate resistant cells as targets for selective chemotherapy. Adv Enzyme Reg 1986; 24: 3–11
  • Mini E, Sobrero A, Moroson BA, et al. Differential efficacy of trimetrexate (2,4-diamino-6-methyl-((3,4,5-trimethoxyanilino) methyl)quinazalone, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro. Proc Am Assoc Cancer Res 1985; 26: 230, abstr
  • Sirotnak F M, Moccio D M, Kelleher LE, et al. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981; 41: 4447–4452
  • Mini E, Moroson B A, Franco CT, et al. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res 1985; 45: 325–330
  • Cowan K H, Jolivet JJ. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem 1984; 257: 10793–10800
  • Frei E, III, Rosowsky A, Wright JE, et al. Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture. Proc Natl Acad Sci (USA) 1984; 81: 2873–2877
  • Ohnoshi T, Ohnuma T, Takahashi I, et al. Establishment of methotrexate resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. Cancer Res 1982; 42: 1655–1660
  • Pizzorno G, Mini E, Coronello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988; 48: 2149–2155
  • Simonsen C C, Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci (USA) 1983; 80: 2495–2499
  • Bertino J R, Srimatkandada S, Carman MD, . Mechanisms of methotrexate resistance in acute leukemia. Normal and Neoplastic Hematopoiesis, DW Golde, PA Marks, et al. Alan R. Liss Inc., New York, 465–478
  • Dedhar S, Hartley D, Goldie JH. Increased dihydrofolate reductase activity in methotrexate-resistant human promyelocytic-leukaemia (HL-60) cells. Biochem J 1985; 225: 609–617
  • Kano Y, Ohnuma T, Holland JF. Folate requirements of methotrexate resistant human acute lymphoblastic leukemia cell lines. Blood 1986; 68: 586–591
  • Biedler J L, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells hi vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30: 1174–1184
  • Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976; 455: 152–162
  • Inaba M, Kobayashi H, Sakurai Y, et al. Active efflux of daunomycin and adriamycin in sensitive and resistant sublines in P388 leukemia. Cancer Res 1979; 39: 2200–2203
  • Klohs W D, Steinkampf R W, Besserer JA, et al. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW 310U. Cancer Lett 1986; 31: 253–260
  • Arkin H, Ohnuma T, Holland JF, et al. Multi-drug (pleiotropic) resistance in trimetrexate (TMQ)-resistant human acute lymphoblastic leukemia (ALL) cell line, MOLT-3. Proc Am Assoc Cancer Res 1986; 27: 269, abstr
  • Ramu N, Ramu A, Pollard HB, et al. Resistance to trimetrexate (TMQ) is related to pleiotropic drug resistance. Proc Am Assoc Cancer Res 1986; 27: 391, abstr
  • Klohs W D, Steinkampf R W, Leopold W R, Fry DW. Potentiation of adriamycin, trimetrexate and an AMSA analog (CI 921) cytotoxicities by amiodarone and reserpine in multidrug resistant P388 cells. Proc Am Assoc Cancer Res 1987; 28: 298, abstr
  • Arkin H, Ohnuma T, Yee ES, et al. Studies of membrane glycoprotein in trimetrexate (TMQ)-resistant human leukemic cells. Proc Am Assoc Cancer Res 1987; 28: 297, abstr
  • Klohs W, Steinkampf R, McMichael A, et al. Development of resistance to the anthrapyrazole CI-937 in L1210 cells. Proc Am Assoc Cancer Res 1989; 30: 523, abstr
  • Assaraf Y G, Molina A, Schimke RT. Amplification of MDR 1 and/or DHFR genes in hamster cells resistant to the lipophilic antifolates trimetrexate and piritrexim. Proc Am Assoc Cancer Res 1989; 30: 477, abstr
  • Assaraf Y G, Molina A, Schimke RT. Cross-resistance to the lipidsoluble antifolate trimetrexate in human carcinoma cells with the multidrug resistant phenotype. J Natl Cancer Inst 1989; 81: 290–294
  • Ramu N, Ramu A, Cole DE, et al. Mechanism of acquired resistance to methotrexate in P388 marine leukemia cells and in their doxorubicin-resistant subline. Isr J Med Sci 1988; 24: 477–482
  • Takemura Y, Ohnuma T, Yee ES, et al. A human leukemic cell line resistant to two new folate analogues, trimetrexate (TMQ) and N10-propargyl-5,8-dideazafolic acid (CB3717). Proc Am Assoc Cancer Res 1987; 28: 276, abstr
  • Hamada H, Tsuruo T. Purification of the 170-to-180-kilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem 1988; 263: 1454–1458
  • Shen D W, Fojo A, Roninson IB, et al. Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol 1986; 6: 4039–4044
  • Akiyama J I, Cornwell M M, Kuwano M, et al. Most drugs that reverse multidrug resistance also inhibit photoaffinity labelling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 1988; 33: 144–147
  • Lincke C R, van der Bliek A M, van der Velde-Koerts T, et al. Phenotype of the wild-type human mdr1 gene. Proc Am Assoc Cancer Res 1989; 30: 519, abstr
  • Scheithauer W, Moyer M P, Clark G M, von Hoff DD. Application of a new preclinical drug screening system for cancer of the large bowel. Cancer Chemother Pharmacol 1988; 21: 31–34
  • Minton M P, Atkinson T, Sherwood RF. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 1987; 156: 1222–1227
  • Romanini A, Chou T C, Bertino JR. Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM lines sensitive and resistant to methotrexate. Adv Enzyme Regul 1989; 27: 28–33
  • Romanini A, Sobrero A F, Chou TC, et al. Folate depletion induced by carboxypeptidase G2 enhances trimetrexate cytotoxicity in vitro and in vivo. Cancer Res 1989; 49: 6019–6023
  • Kalghatgi K K, Moroson B A, Horvath C, Bertino JR. Enhancement of antitumor activity of 2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (Triazinate) with carboxypeptidase G1. Cancer Res 1979; 39: 3441–3445
  • Leopold W R, Dykes D D, Griswold DP, Jr. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, cytoxan, 6-thioguanine, 5-fluorouracil vincristine or cisplatin against P388 leukemia. Proc Am Assoc Cancer Res 1986; 27: 253, abstr
  • Fry DW. Cytotoxic synergism between trimetrexate and etoposide in L1210 cells: trimetrexate-mediated potentiation of the proteinassociated DNA strand breaks produced by etoposide. Proc Am Assoc Cancer Res 1988; 29: 483, abstr
  • Sobrero A, Romanini A, Russello O, et al. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 1989; 25: 977–982
  • Howard C T, Hook K E, Leopold WR. Sequence and schedule dependent synergy of trimetrexate in combination with 5-fluorouracil or cisplatin. Proc Am Assoc Cancer Res 1987; 28: 417, abstr
  • Mini E, Mazzei T, Coronello M, Periti P. Comparative effects of two non-classical antifolates, trimetrexate (TMQ) and triazinate (TZT) on 5-fluorouracil (FURA) cytotoxicity against human CCRF-CEM leukemia cells. Proc Am Assoc Cancer Res 1989; 24: 475, abstr
  • Sobrero A, Romanini A, Russello O, et al. Trimetrexate-fluoropyrimidines vs methotrexate-fluoropyrimidines: implications of their identical sequence dependent interactions in vitro. Eur J Cancer, in press
  • Galivan J, Nimec Z, Rhee M. Synergistic growth inhibition of hepatoma cells exposed in vitro, to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine. Cancer Res 1987; 47: 5256–5260
  • Galvan J, Nimec Z, Rhee M, et al. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate. Cancer Res 1988; 48: 2421–2425
  • Galivan J, Rhee M S, Johnson TB, et al. The role of cellular folates in the enhancement of activity of the thymidylate synthase inhibitor 10-propargyl-5,8-dideazafolate against hepatoma cells in vitro by inhibitors of dihydrofolate reductase. J Biol Chem 1989; 264: 10685–10692
  • Thorndike J, Gaumont Y, Powers J, et al. Synergistic growth inhibition of human lymphoma cells by combination of trimetrexate with 5,10-dideazatetrahydrofolate. Proc Am Assoc Cancer Res 1988; 29: 285, abstr
  • Gaumont Y, Kisliuk R, Emkey R, et al. Folate enhancement of antifolate synergism in human leukemia cells. Proc Am Assoc Cancer Res 1989; 30: 474, abstr
  • Allegra C J, Kovacs J A, Drake JC, et al. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med 1987; 165: 926–931
  • Kovacs J A, Allegra C J, Kennedy S, et al. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of a rodent Pneumocystis carinii pneumonia. Am J Trop Med Hyg 1988; 39: 491–496
  • McCormack J J, Heusner J J, Hacker MP, et al. Further pharmacological studies of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino) methyl] quinazoline (NSC 249007;TMQ). Proc Am Assoc Cancer Res 1981; 22: 245, abstr
  • Heusner J J, Tong W P, McCormack JJ, et al. Disposition of the non-classical folate antagonist 2,4-diamino-5-methyl-6-(3,4,5-trimethoxyanilino) methyl quinazoline (TMQ; trimetrexate) in mice. Proc Am Assoc Cancer Res 1985; 26: 234, abstr
  • Andrews L, McGhee C, Anderson J, et al. Preclinical toxicological evaluation of the chemotherapeutic agent trimetrexate. Proc Am Assoc Cancer Res 1985; 26: 370, abstr
  • Gans J H, Tong W P, Whitfield LR, et al. Pharmacokinetic studies with trimetrexate in dogs. Proc Am Assoc Cancer Res 1986; 27: 405, abstr
  • Marsh JC. Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells. Cancer Treat Rep 1982; 66: 499–504
  • Bogliolog V G, Lerza R A, Manlio PM, et al. Toxicity of trimetrexate on hemopoietic progenitor cells in normal mice. Anticancer Res 1988; 8: 229–232
  • Rosenthal G J, Germolec D R, Lam KR, et al. Comparative effects on the immune system of methotrexate and trimetrexate. Int J Immunopharmacol 1987; 9: 793–801
  • Rosenthal G J, Weigand G W, Germolec DR, et al. Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action. J Immunol 1988; 141: 410–416
  • Duch D S, Edelstein M P, Nichol CA. Inhibition of histamine-metabolizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists. Mol Pharmacol 1980; 18: 100–104
  • Gans J H, Tong W P, Whitfield LR, et al. Dose proportionality study of trimetrexate oral absorption in dogs. Proc Am Assoc Cancer Res 1987; 28: 433, abstr
  • Tong W P, Gans J R, Whitfield LR, et al. Relative bioavailability study of trimetrexate in dogs. Proc Am Assoc Cancer Res 1988; 29: 505, abstr
  • Wong B, Whitfield L, Change T, Woolf T. Identification of major metabolites of trimetrexate in urine and bile of rat. Proc Am Assoc Cancer Res 1989; 30: 537, abstr
  • Whitfield L, Chang T, Wong B. Distribution of 14C-trimetrexate in tissues of male and female rats. Proc Am Assoc Cancer Res 1989; 30: 533, abstr
  • Webster L K, Tong W P, McCormack JJ. Metabolism and biliary excretion of trimetrexate by the isolated perfused rat liver. Cancer Lett 1987; 29: 65–71, abstr
  • Tong W P, Mathews L A, McCormack JJ. Disposition of trimetrexate (TMTX) in the isolated perfused mouse liver. Proc Am Assoc Cancer Res 1987; 28: 435, abstr
  • Balis F M, Lester C M, Poplack DG. Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 1986; 46: 169–174
  • Hudes G R, La Creta F, Delap RJ, et al. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. Cancer Chemother Pharmacol 1989; 24: 117–122
  • Stetson P L, Shukla U A, Ensminger WD. Stability of trimetrexate, a new non-classical antifolate, in infusion solutions. J Chromatogr 1989; 464: 163–171
  • Donehower R C, Grochow L B, Ettinger ES. Phase I study of trimetrexate. Minutes Phase I Working Group and Biochem Modulators Advisory Group. Washington, DC July 17–18, 1985; 101–106
  • Reece P A, Morris R G, Bishop JF, et al. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer. Cancer Res 1987; 47: 2996–2999
  • Bishop J F, Raghavan D, Olver IN, et al. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. Cancer Chemother pharmacol 1989; 24: 246–250
  • Grochow L B, Noe D A, Dole GB, et al. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst 1989; 81: 124–130
  • Hudes G R, Comis RL. Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer. Semin Oncol 1988; 15: 41–45, suppl 2
  • Maroun JA, Natale R B, Robert F. Trimetrexate combined with cisplatin or etoposide in the treatment of nonsmall cell lung cancer: a pilot study. Semin Oncol 1988; 15: 38–40, suppl 2
  • Hudes G, La Creta F, Walczak J, et al. Phase I pharmacologic study of trimetrexate (TMTX) and cisplatin (DDP) in combination. Proc Am Assoc Cancer Res 1989; 30: 246
  • Stewart JA. Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients refractory to conventional therapy or for which no conventional therapy exists. Semin Oncol 1988; 15: 10–16, suppl 2
  • Ho D HW, Covington W P, Legha SS, et al. Clinical pharmacology of trimetrexate. Clin Pharmacol Ther 1987; 42: 351–356
  • Grem J L, Ellenberg S S, King S A, Shoemaker DD. Correlates of severe or life-threatening toxic effects from trimetrexate. J Natl Cancer Inst 1988; 80: 1313–1318
  • Eisenhauer E A, Zee B C, Pater J L, Walsh WR. Trimetrexate predictors of severe or life-threatening toxic effects. J Natl Cancer Inst 1988; 80: 1318–1322
  • Weiss R B, James W D, Major WB, et al. Skin reactions induced by trimetrexate, an analog of methotrexate. Invest New Drugs 1986; 4: 159–163
  • Chawla SP, Kavanagh J J, Freedman RS, et al. Pulmonary toxicity and limited activity of trimetrexate in recurrent carcinoma of the uterine cervix. Proc Am Assoc Cancer Res 1988; 29: 207, abstr
  • King S A, Grem JL. Acute allergic reactions to trimetrexate. Proc Am Soc Clin Oncol 1988; 7: 7, abstr
  • Ackerly C A, Hartshorn J, Tong WP, et al. A rapid and sensitive method for determination of trimetrexate from biological fluids. J Liq Chromatog 1985; 8: 125–134
  • Rogers P, Allegra C J, Murphy RP, et al. Bioavailability of oral trimetrexate in patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother 1988; 32: 324–326
  • Tong W P, Stewart J A, McCormack JJ, et al. Metabolism of 2,4-diamino-5-methyl-6-(3,4,5-trimethoxyanilino) methylquinazoline (trimetrexate, TMQ) in man. Proc Am Soc Clin Oncol 1985; 4: 31, abstr
  • McCormack J J, Webster L K, Tong WP, et al. Studies of a metabolite of trimetrexate. Proc Am Assoc Cancer Res 1986; 27: 256, abstr
  • Kris M G, D'Acquisto R W, Gralla RJ, et al. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. Am J Clin Oncol 1989; 12: 24–24
  • Costanza M E, Korzon A H, Rice M A, Wood WC. A phase II study of trimetrexate in previously untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 1988; 7: 30, abstr
  • Ajani J, Abbrezzese J, Blackburn R, et al. Phase II evaluation of trimetrexate (TMTX) in patients with advanced colorectal carcinoma (CRC). Proc Am Soc Clin Oncol 1988; 7: 115, abstr
  • Sternberg C N, Yagoda A, Scher H, et al. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Eur J Cancer Clin Oncol 1989; 25: 753–754
  • Doroshow J, Odujinrin O, Flam M, et al. Trimetrexate in locally advanced or metastatic adenocarcioma of the pancreas: a phase I study of the Northern California Oncology Group. Proc Am Soc Clin Oncol 1989; 8: 111, abstr
  • Brown T, Fleming T, MacDonald J. A randomized trial of two schedules of trimetrexate (TMTX) versus 5-fluorouracil (5FU) in colorectal carcinoma: a Southwest Oncology Group study. Proc Am Soc Clin Oncol 1988; 7: 109, abstr
  • Young FE. The role of the FDA in the effort against AIDS. Public Health Rep 1988; 13: 242–245
  • Green J A, Dawson A A, Fell LF. Measurement of drug dose intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol 1980; 9: 511–514
  • Hryniuk W, Bush H. The importance of dose intensity in the chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.